Pushpa Bhargava questions DBT guidelines on transgenic crops

Even as the Genetic Engineering Appraisal Committee (GEAC) decided to constitute a sub-committee to review the toxicology data generated by two applicants for genetically modified brinjal, biologist and Padma Bhushan award winner Dr. Pushpa M. Bhargava has questioned the guidelines of the Department of Biotechnology (DBT) on transgenic crops.

Dr. Bhargava and others had asked for the raw data on toxicity studies on rats using transgenic brinjal which were carried out by Dr. Sesikeran, former Director of National Institute of Nutrition at Hyderabad. He found statistically quite significant differences between rats fed on Bt Brinjal and those fed on a normal meal in respect of several important parameters, said Dr. Bhargava.

However, Dr. Sesikeran had said that as all the values (both of the control and of the experimental animals) fell within the normal range of variation, the differences were not significant, and that there was no need to repeat the experiment.

Our point was that if on repetition the same differences are found again, they are bound to be significant, Dr. Bhargava pointed out. Further, he used only 20 animals (10 female and 10 male) in both experimental and the control groups which is the minimum number for such tests. Dr. Sesikeran must explain why only a minimum number was used, he said.

In a letter to Dr. Ranjini Warrier, member secretary, GEAC, on July 23, Dr. Bhargava, who was responding to the two e-mails of July 20 from Dr. Sesikeran to all the members of GEAC, said, According to Dr. Sesikeran, DBT guidelines of 2008 say the following in regard to Interpretation of results of safety studies: The design and analysis of the study should be kept as simple as possible, avoiding unnecessarily complex, sophisticated statistical techniques. If the design is simple, the statistics are likely to give straightforward results. Non-statistical knowledge must be applied in study design and proper interpretation of the biological significance of the results. Just because two treatments are statistically significantly different does not mean that the difference is large enough to have any biological importance or any practical significance.

Dr. Bhargava said he would like to know which international body endorsed this, as scientifically it does not make any sense. He said he didnt understand what that meant and sought a clarification. The GEAC meets next in August.

Follow this link:
Pushpa Bhargava questions DBT guidelines on transgenic crops